Inventiva Completes Final Patient Visit in NATiV3 Phase 3 Trial; Topline Data Due Q4 2026
IVA sits 46% above its 52-week low of $3.35.
Summary
Inventiva announced the last patient completed their final visit in the NATiV3 Phase 3 trial of lanifibranor in MASH, with topline results expected in Q4 2026. The company also revised its H1 2026 financial results date to September 28, 2026.
Key Events · Product Development and Regulatory · IVA
-
NATiV3 Trial Enrollment Complete
Last patient completed final 72-week visit in the Phase 3 NATiV3 trial of lanifibranor in MASH. Main cohort enrolled 1,009 patients with F2/F3 fibrosis; exploratory cohort enrolled 410 patients with F1-F4 fibrosis.
-
Topline Results Expected Q4 2026
Inventiva expects to report topline NATiV3 results in Q4 2026. If favorable, regulatory submission is anticipated in H1 2027 with potential U.S. launch in 2028, subject to FDA approval.
-
H1 2026 Financial Results Date Revised
H1 2026 financial results publication moved to Monday, September 28, 2026, from the previously disclosed date of Friday, September 25, 2026. Conference call scheduled for 8:00 am ET / 2:00 pm Paris.
-
September Investor Conferences
Management will present at Morgan Stanley Global Healthcare Conference (Sept 15), Stifel Cardiometabolic Forum (Sept 30), and Jefferies Healthcare C-Suite Series (Sept 30).
Analysis · IVA · Life Sciences
The last patient has completed the final 72-week visit in the NATiV3 Phase 3 trial of lanifibranor in MASH, with 1,009 patients in the main cohort and 410 in an exploratory cohort. This is the pivotal event that unlocks the topline readout expected in Q4 2026 — the single most important catalyst for Inventiva's valuation. If results are favorable, the company plans regulatory submission in H1 2027 and a potential U.S. launch in 2028. The company also moved its H1 2026 financial results to September 28, 2026, from September 25.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1872 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IVA was trading at $4.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $3.35 to $7.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.